Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Alx Oncology Holdings Q3 2026 Results: Net Loss of $21.8M, Loss Narrows

ALX Oncology reported a net loss of $57.7 million for the nine months ended September 30, 2026, an improvement from the $78.8 million loss in the prior year period. The company significantly strengthened its balance sheet through equity offerings, increasing total stockholders' equity to $125.9 million from $26.0 million at the end of 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-21.8-22.1
EPS (diluted, $ a share)$-0.15$-0.41

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ALXO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Alx Oncology Holdings Inc: key numbers

Share price
$1.00Close, Nov 17
Market cap
$130M
Shares outstanding
129.27MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Alx Oncology Holdings Inc

All →
8:11 AM ET 8-K
Financial Results

Alx Oncology Holdings Financial Results

ALX Oncology reported third quarter 2026 financial results, ending the period with $147.2 million in cash and investments, which is expected to fund operations through the first half of 2028. The company highlighted clinical progress for evorpacept and ALX2004, with topline data from the ASPEN-09-Breast trial now expected in the second half of 2027.

“Throughout the third quarter, we continued to make significant progress across both the ASPEN-09-Breast and ALX2004 clinical trials. The recent publication of ASPEN-06 results in Nature Medicine further reinforces the promise of evorpacept and our biomarker-driven development strategy.”

Jason Lettmann, Chief Executive Officer of ALX Oncology
4:56 PM ET 8-K
Other 8-K Filing

Alx Oncology Holdings Other 8-K Filing

ALX Oncology entered into exchange agreements with certain stockholders, including funds affiliated with Blackstone, RA Capital, and venBio, to exchange 13,353,384 shares of common stock for an equivalent number of pre-funded warrants. This transaction is a non-cash exchange of equity classes intended to manage beneficial ownership levels, as the warrants include exercise limitations to prevent holders from exceeding specific ownership thresholds.

Counterparty
Blackstone Annex Master Fund L.P.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.